Life
Science

Physics & Engineering

 

Sort by: Date | Licensing Manager
Home › Technologieangebote
Your search found 40 results

Chemerin9 Variants for Diagnosis and Therapy of Pancreatic and Oesophageal Cancer


07.03.2012 | Ref.Nr. 11115
Download as PDF PDF Download Share
Life Science › Medical Devices › Imaging

Imaging of subcutaneous oesophageal tumors at the flanks of the animals with labeled vChem9 peptide (source: Grötzinger, Bandholz, NP2D 2011).Background
Pancreatic and oesophageal tumors are comparatively rare but characterized by high mortality rates. One reason is that such tumors are commonly detected only at advanced stages of cancerous disease. Often the disease is detected by chance, for instance during the course of other medical examinations.

Technology
Occurrence of CMKLR1, a G protein-coupled receptor, was found to be elevated in oesophageal squamous cell carcinoma and pancreatic adenocarcinoma. We offer peptidic variants of CMKLR1 ligand Chemerin9 with highest stability and optimized ligand binding properties. Attached to a detectable label or therapeutically active agent the peptide variants are suitable for imaging of mestastases formation in pancreatic and oesophageal tumors and its therapy in a theranostic approach.
 

IP Rights
European priority application filed

Patent Owner
Charité – Universitätsmedizin Berlin

Application Area:
Predictive imaging, Therapy monitoring, Micro-dosing approach
Development Stage: in vivo
Tags: Imaging, micro dosing delivery, theranostics, tumor therapy,
Further Categories: Diagnostics, Life Science, Medical Devices, Imaging
Dr. Janin Hofmann's picture
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Suitable Industry: Diagnostics, Biotechnology, Pharmaceuticals
Benefits:
  • Reliable diagnosis of primary pancreatic and oesophageal tumors
  • Promising Target: CMKLR1
  • Reliable detection of early metastases
  • Suitable for routine medical screening

Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases


15.02.2012 | Ref.Nr. 09061
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Biphosphonate with a prolonged carbon chain.Background
Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) - the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases.

Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis.


IP Rights
EP Application (08/2009).
PCT Application (08/2010).
A PCT application was filed in August 2010.

Patent Owner
Humboldt-Universität zu Berlin
Rheinisch-Westfälische
Technische Hochschule Aachen (RWTH)

Application Area:
Drug candidates for the treatment of inflammatory lung diseases, cystic fibrosis and atherosclerosis.
Development Stage: Ex vivo
Tags: Acid Sphingomyelinase, athero-sclerosis, bisphosphonate, cystic fibrosis, inflammatory lung diseases, Inhibitor,
Further Categories: Life Science, Medical Devices, Pharma & Biotech
Dr. Bettina Büttner's picture
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Suitable Industry: Pharmaceuticals
Benefits:
  • Neutral sphingomyelinase is not influenced
  • First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent
  • Inhibition of dexamethasone induced apoptosis was proven in vitro
  • Substances can easily be synthesized in a one-step or two-step procedure
  • Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate

 

C3bot Peptides as Drugs for the Treatment of Traumatic or Degenerative Neuronal Injury


21.12.2011 | Ref.Nr. 08167
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Figure : Neurocyte Picture: Höltje et al. 2009Background
Peptide fragments of the C3 exoenzyme of Clostridium botulinum have been found to have neuritogenic effects on neurons as well as regenerative proper-ties in an animal model (mouse). The peptides represent promising drug candidates for the treatment of neurodegenerative disorders such as Morbus Alzheimer, Parkinson, Huntington chorea but also for spinal cord injury and traumatic brain injury.enic effects on neurons as well as regenerative properties in an animal model (mouse).

Technology
We offer neuron-specific short peptides for the treatment of neurodegene-rative disorders. Whereas a 26mer peptide stimulates both, dendritic and axonal growth, a 15mer peptide selectively promotes axonal growth. Both, the 15mer and the 26mer peptide trigger a strong transient activation of RhoA which mimics the physiological conditions of RhoA activation / inactivation cycles.
These properties make the peptides suitable for repeated administration and long term treatments. As the peptides only act on neurons and not on microglia or astrocytes, there is no risk for neuronal inflammation or glia scar formation.

 

IP Rights
PCT application in 2010
National applications in USA/Europe in 2011

Patent Owner
Charité – Universitätsmedizin Berlin
Hannover Medical School

Application Area:
Drug candidates for the treatment of neurodegenerative disorders
Development Stage: In vitro / in vivo
Tags: drug candi-date, Huntington cho-rea, Morbus Alzheimer, neurodegenerative disorders, Neuron-specific peptides, spinal cord injury, traumatic brain injury,
Further Categories: Life Science, Pharma & Biotech
Dr. Janin Hofmann's picture
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Benefits:
  • Physiological acting neuritogenic drug – small size and effective in nanomolar concentrations
  • Act neuron-specific -> reduced risk for neuronal inflammation or glia scar formation
  • Short peptides with low antigenicity and good kinetics
  • Broad application areas: Spinal cord injury, traumatic brain injury, Morbus Alzheimer, Parkinson, Huntington Chorea, etc.
  • In vivo data on spinal cord injury model show regenerative properties

Cytokinin Receptor Antagonists and Compositions Containing these Derivatives


08.12.2011 | Ref.Nr. 07114
Download as PDF PDF Download Share
Life Science › Nutrition

Generel formular of alylbenzylamino Picture: WO 2009/043320 A2 Background
Cytokinins are plant hormones involved in cell division, shoot meristem and leaf formation, chloroplast biogenesis, and senescence. The development of agonists and antagonists with a particular physiological effect is useful in mechanism-of-action studies of biologically active natural products. The potent naturally occurring cytokinin N6-isopentenyladenine served as the basis for initial structure-activity studies.

Technology
We offer substituted 6-(alkylbenzylamino)-purin derivatives as cytokinin receptor antagonists to provide cytokinin analogons for growth regulation in plants and to offer the possibility for a specific selectivity for cytokinin receptors without being toxic for animal cells. The derivatives can be used to influence morphology, leading to:
  • Increased root growth, fruit or grain size
  • Stimulation of root branching and enhanced number of lateral roots
  • Accelerated seed germination
  • Enhanced yield and quality of crops

 
IP Rights
Czech Patent Application was filed in 2007
PCT Patent Application was filed in 2008
National applications filed in USA and Europe

Patent Owner

  • Freie Universität Berlin
  • Palacky University Olomouc (CZ)
Application Area:
Applicable as plant growth regulator
Development Stage: Green house (plant model Arabidopsis thaliana)
Tags: 6-(alkylbenzylamino)-purin derivatives, cytokinin analogons, cytokinin receptor antagonist, Plant Growth Regulator, Purin Derivatives,
Further Categories: Life Science, Nutrition
Dr. Bettina Büttner's picture
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Suitable Industry: Agriculture industry
Benefits:
  • Non toxic for animal cells
  • Efficiency is proven in various test systems
  • Suitable regulator for proliferation and morphogenesis in tissue culture

One-Plasmid Systems for Blue-light-regulated Gene Expression in Prokaryotes


18.08.2011 | Ref.Nr. 11043
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Background
Protein expression systems are very widely used in the life sciences, biotechnology and medicine. Traditional strategies for recombinant protein expression involve the transformation of a gene expression vector into prokaryotic expression hosts and culturing the cells so that they express the desired protein. Using an inducible expression cassette the onset of the protein expression can be controlled by several inducer (f.e. chemical, temperature, cold).

Technology
We offer two compact plasmids for facile light regulated expression of target proteins in prokaryotic hosts. Dependent from the application, one plasmid can be used for light activated and one for light inactivated gene expression. Both plasmids are working without exogenous addition of chromophores or expensive chemical inducers and allow a specific, spatially- and temporally precise control of protein expression. A competitive advantage is the use of light as inducer especially for the production of recombinant proteins. Another advantage is the very precise control of protein expression which is very relevant for several research applications. By using standard chemical inducers a spatially and temporally precise control of protein expression is not possible.

IP Rights
None

Origin
Humboldt University, Berlin
Application Area:
Production of proteins in prokaryotes Analysis of protein functions in prokaryotes Pulsed induction of protein expression for several research applications
Development Stage: Product
Tags: Automated induction, Escherichia coli, Light induction, Prokaryote, Protein expression, Pulsed induction, Recombinant protein,
Further Categories: Life Science, Pharma & Biotech
Dr. Bettina Büttner's picture
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Suitable Industry: Biotechnology and pharmaceutical industry, Research & Development
Benefits:
  • One plasmid is designed for light inactivated and one for light activated gene expression
  • Both plasmids are compact and ready-to-use
  • No exogenous addition of chromophores or chemical inducers is required
  • System facilitates pulsed and/or automated induction of protein expression
  • Allows specific, spatially- and temporally-precise control of protein expression
  • Reduced production costs, because expensive chemical inducers are not required

Stereoselective Synthesis of cis-4-methylsphingosine and derivatives thereof


24.06.2011 | Ref.Nr. 10127
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Background
Sphingosine-1-phosphate is a bioactive lipid signaling molecule and an agonistic ligand of five specific G protein coupled receptors named S1P1-5.These receptors play a crucial role in the cardiovascular and immune system and in angiogenesis. The known compound FTY720 (Fingolimod) is a sphingosine analogue with immunosuppressive effects and was recently approved for treatment of multiple sclerosis in the United States and Russia.The synthetic sphingosine analogue Cis-4-methylsphingosine was firstly synthesized by R. R. Schmidt and coworkers in 1993 in nine steps.Similar to FTY720 this compound is phosphorylated in biological systems and inhibits the activity of different S1P-receptors, however the spectrum of receptors influenced by Cis-4-methylsphingosine is slightly different to that influenced by FTY720. Cis-4-methylsphingosine induces apoptosis of neuroblastoma cells.

Technology
We offer a rapid and simple method for the stereoselective synthesis of cis-4-methylsphingosine and derivatives thereof in only two steps. The novel synthesis is characterized by using easily accessible starting material, and an overall yield of nearly 30% which is almost 100-fold compared to the synthesis known in the art. Since Cis-4-methylsphingosine also influences S1P-receptors like FTY70, however with a slight different spectrum, this compound might have similar effects or might support or supplement the activity of FTY720. Thereby Cis-4-methysphingosine has a great potential for pharmaceutical application.   

IP Rights
EP patent application was filed in May 2011
 
Patent Owner
Humboldt-Universität zu Berlin

 

Application Area:
Preparation of cis-4-methylsphingosine
Development Stage: Proof of concept
Tags: cis-4-methylsphingosine, FTY720, stereoselective synthesis,
Further Categories: Life Science, Pharma & Biotech
Dr. Bettina Büttner's picture
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Suitable Industry: Chemical, biotechnology and pharmaceutical industry
Benefits:
  • Reliable, easy and rapid method for the preparation of cis-4-methylsphingosine
  • Only two steps form starting material to cis-4-methylsphingosine
  •  Cost- and time-effective synthesi100-fold higher yield compared to state of the art synthesis 

New Pill Package - Applicator for Ointments


12.05.2011 | Ref.Nr. 10049
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

The invention offers two new packaging methods for pills and ointments. Advantage of the packagings is the one-hand operation and the sterile application of the drug.

Pills are fixed on a carrier item that is airtight sealed in a blister-like packaging. It enables the patient to take the pill sterile with one hand from the carrier item. Particularly, the pill goes straight to the mouth of the patient and any contact with the possibly unwashed hands or the non-sterile environment is avoided.

The invented pill dispenser can have marks for the weekdays and daytimes. Additionally it has a fixed patient information leatflet, so that a mixing up with other drugs becomes excluded.

For the sterile application of an ointment a small map packaging was invented. Therefore, the ointment is airtight sealed on a cushion at the end of a rodlike carrier item. The rodlike carrier items are alternating fixed on the map packaging and one map contains as many dosages as needed for one day.

The patient is able to apply target-oriented a defined dosage of one use sterile at every time and everywhere. Therefore, the packaging is special on the way extremely convenient.

IP Rights
German Patent Application, filed on August 6, 2010

Origin
Hochschule für Technik und Wirtschaft Berlin, Germany

Application Area:
Drug packaging
Development Stage: Prototyp
Type of Collaboration: License
Tags: blister, dosage, one-hand, package, pill, sterile,
Further Categories: Life Science, Medical Devices, Pharma & Biotech
Dr. Janin Hofmann's picture
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Market Potential: Worldwide
Benefits:
  • Sterile application of drugs
  • One-hand operation
  • Simply application being on the way

Peptides for Diagnosis and Therapy of Celery Allergy and of Hazelnut Allergy


10.11.2010 | Ref.Nr. 10048
Download as PDF PDF Download Share
Life Science › Diagnostics

Novel linear IgE-binding peptide epitopes of the major celery allergen api g1 have been identified which are suitable for the diagnosis and therapy of celery allergy. The peptide epitopes can also serve as a basis for the detection of api g1 allergens in food and other  products. Based on the novel peptides, a high specific assay was developed which allows to distinguish between celery allergic patients and healthy individuals.

Celery is a frequent cause of food allergy in pollen-sensitized patients and may induce severe allergic reactions. Allergic reactions against celery are of major clinical relevance due to celery's wide presence in convenience foods and spice. Approximately 3% - 4% of the European or American population and 5% of young children are affected by immunoglobulin E (IgE)  mediated food allergy; 30% of them are sensitized to celery. The symptoms ranging from mild oral pruritus to a possible life-threatening anaphylactic shock.

IP Rights
An EP application was filed in July 2010.

Origin
The invention was made at the Charité – Universitätsmedizin Berlin.

Application Area:
Pharma, Diagnostic, Food analytic
Development Stage: Pilot study, in vitro
Type of Collaboration: Licence
Tags: Allergen, Allergy, Celery, Diagnosis, Food, Hazelnut, Peptide, Therapy,
Further Categories: Diagnostics, Immunology & Infection, Nutrition, Pharma & Biotech
Dr. Bettina Büttner's picture
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:
  • Allows a specific and fast identification of the api 1g allergen in celery allergic patients
  • More reliable results compared to PCR- or state of the art- IgE-detection approaches are supposed
  • Peptide is suitable for chip applications and automatable methods
  • The novel peptides can be used for the desensitization of patients (Immunotherapy)

Aptamers for Treatment and Diagnosis of Autoantibody Based Dilated Cardiomyopathy


28.07.2010 | Ref.Nr. 09014
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

We offer novel high affinity aptamers which inhibit the agonistic effect of autoantibodies specific for the second extracellular loop of human beta1-adrenergic receptors. Antibodies to the beta1-adrenergic receptor are detected in approximately 70% of idiopathic dilated cardiomyopathy patients and in nearly 100% of patients with Chagas’ cardiomyopathy and peripartum cardiomyopathy.

The typical characteristics of these heart muscle disorders are ventricle enlargement and the inability to pump enough blood for the body‘s needs and finally severe heart failure. For idiopathic dilated cardiomyopathy, the prevalence is 36 cases per 100,000 people and the incidence is 1–2 cases per 100,000 people per year, whereas for Chagas’ cardiomyopathy (based on the whole population of Latin America) the prevalence is 1000 cases per 100,000 people and the incidence is 10 cases per 100,000 people per year. The incidence of peripartum cardiomyopathy shows regional differences from 1 in 300 live births in Haiti to 1 in 1300-4000 live births in the US. The novel aptamers strongly inhibit the agonistic effect of beta1-adrenergic receptor-directed autoantibodies isolated from patients with idiopatic dilated cardiomyopathy, Chagas’ cardiomyopathy and peripartum cardiomyopathy, as demonstrated in a bioassay analyzing the beating frequency of rat cardiomyocytes. The specificity of the new aptamers to the autoantibodies relevant for the indicated cardiomyopathies has potential in the development of valuable new agents for diagnostic and therapeutic applications.

IP Rights
An EP application was filed on 29 June, 2010.

Origin
• Charité – Universitätsmedizin Berlin
• Max-Delbrück –Centrum für Molekulare Medizin Berlin-Buch
• Aptares AG

Application Area:
Pharma, Diagnostics
Development Stage: In vitro
Type of Collaboration: License
Tags: Aptamer, Auto-Antibodies, Beta1-Adrenergic Receptor, Cardiomyopathy, Diagnostic, Dilated Cardiomyopathy,
Further Categories: Cardiology, Diagnostics, Life Science, Pharma & Biotech
Dr. Bettina Büttner's picture
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Suitable Industry: Pharma, Diagnostic
Market Potential: Worldwide
Benefits:
  • Possible new therapeutic applications in idiopathic dilated cardiomyopathy, Chagas’ cardiomyopathy and peripartum cardiomyopathy.
  • Very effective treatment options
  • Treatment is presumably associated with low side-effects.
  • The aptamers shows IC50 values of 100 nM or less in a rat cardiomyocyte beating assay (the antibody-mediated beating frequency increase is normalized).
  • The aptamers are also suitable as binders for the pathogenic autoantibodies in apheresis: an alternative to the costly and risky apheresis based on immunoadsorption.
  • Possible application: the diagnosis of autoantibody-based cardiomyopathies
  • The aptamers have promising advantages:
    - Production is fast and cheap
    - A wide variety of chemical modifications is possible
    - The kinetic parameters can be changed on demand
    - High affinity and specificity
    - Aptamer activity can be controlled by the application of antidotes

CEACAM8: Promising Therapeutic Agent with Pleiotropic Effects


09.07.2010 | Ref.Nr. 05100
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Granulocytes form the first and fastest line of defense against pathogenic infections. They participate in the inflammatory reaction by phagocytosis, release of cytotoxic compounds and pro-inflammatory cytokines and generation of ROS.

Most recently it was shown that membrane-anchored CEACAM8 triggers apoptosis in granulocytes. Thus, substances binding specific to membrane-bound CEACAM8 are useful to treat human autoimmune diseases or gout.  

We offer soluble CEACAM6 or CEACAM8 proteins to manufacture a medicament for prophylactic or therapeutic treatment of human autoimmune diseases, gout, cancer or infection diseases.

Moreover, we offer antibodies directed against CEACAM8 or CEACAM6 that inactivate the functions triggered by soluble CEACAM6 and CEACAM8, respectively. Thus, the specific antibodies can be utilized as therapeutcis to prevent the pleiotropic effects induced by physiological released CEACAMs.

IP Rights
European patent applications filed in November 2005 and September 2007. US patent application filed in October 2006.

Origin
The technology was developed at the Charité (Berlin/Germany).

Application Area:
Pharma, Medicine
Development Stage: Lab scale
Type of Collaboration: License
Tags: Apoptosis, Autoimmune, CEACAM8, Granulocytes, Infections, Inflammatory, Membrane, Therapeutic, Toxic,
Further Categories: Life Science, Immunology & Infection, Medical Devices, Pharma & Biotech
Marcel Tilmann's picture
Licensing Manager: Marcel Tilmann
T +49 30 2125 4827
F +49 30 2125 4822
marcel.tilmann@ipal.de
Market Potential: Worldwide
Benefits:
  • CEACAM8 is a human molecule that can be produced in high purity
  • Recombinant (soluble) CEACAM8 regulates various functions of CEACAM1 expressing cells
  • CEACAM8 binds the adhesion receptor of CEACAM1 that is expressed on leucocytes, epithelial cells and activated endothelial cells
  • CEACAM8 is non-homophilic and thus does not inactivate itself during storage
  • CEACAM8 does not bind pathogens, as other CEACAMs do à pathogens cannot inactivate CEACAM8
  • Principle can be used as therapeutic approach in various indications